Background: Mutations in canonical transient receptor potential channel 6 (TRPC6) have been identified as responsible for the development of focal segmental glomerulosclerosis, a proteinuric disease with steroid resistance and poor prognosis. This study explores the prevalence of TRPC6 variants in Chinese children with idiopathic nephrotic syndrome (INS), the genotype/phenotype correlation of TRPC6 variants, the therapeutic response, and the underlying molecular mechanism. Methods: Fifty-one children with sporadic INS were enrolled: 23 steroid-sensitive cases and 28 steroid-resistant cases. Polymerase chain reaction was used to amplify 13 exons and the promoter sequences of TRPC6 before sequencing. The expression of TRPC6 in renal tissues was illustrated by immunohistochemistry staining. The transcriptional activity of variants in TRPC6 promoter was measured by the luciferase assay. results: Three variants (-254C>G, rs3824934; +43C/T, rs3802829; and 240 G>A, rs17096918) were identified. The allele frequency of the -254C>G single-nucleotide polymorphism (SNP) in the steroid-resistant nephrotic syndrome (SRNS) patients (40.5%) was higher than that in the steroid-sensitive nephrotic syndrome subjects (27.1%; P = 0.046). The -254C>G SNP enhanced transcription from TRPC6 promoter in vitro and was associated with increased TRPC6 expression in renal tissues of SRNS patients. conclusion: -254C>G, a SNP underlying enhanced TRPC6 transcription and expression, may be correlated with the development of steroid resistance in Chinese children with INS.
i diopathic nephrotic syndrome (INS) is a group of proteinuric disorders with a heterogeneous pathogenesis. The histological features range from minimal change nephrotic syndrome to focal segmental glomerulosclerosis (FSGS), with variable responses to glucocorticoids, the mainstay antiproteinuria treatment (1). FSGS is a major cause of proteinuria and renal failure (2) . It is responsible for 5-20% of all cases of end-stage kidney disease in the USA, and besides urogenital and kidney malformations, it is the main cause of end-stage kidney disease in children (2) (3) (4) . Approximately 90% of the pediatric INS cases are steroid responsive (steroid-sensitive nephrotic syndrome (SSNS)), and 10% of the cases account for steroidresistant nephrotic syndrome (SRNS) (5) . Glucocorticoid resistance is an important risk factor for the poor outcome and development of end-stage renal disease within 5 y (6,7).
Mutations in genes encoding podocyte proteins, such as NPHS1, NPHS2, ACTN4, CD2AP, PLCE1, and TRPC6 (8, 9) , have been identified in patients with SRNS. These proteins have been proven essential for the signaling initiated from the slit diaphragm, which is the key component of the glomerular filtration barrier (10) . Therefore, these mutations may contribute to disrupted filtration function and increased protein permeability. The genetic defects found in podocytes provide a better understanding of the pathogenesis of INS and their poor therapeutic responses (11, 12) . In addition, these gene mutations have been shown to be associated with a reduced incidence of relapse of proteinuria upon renal transplantation (13) . One of these proteinuria candidate genes, canonical transient receptor potential channel 6 (TRPC6), encodes TRPC6 protein, a Ca 2+ -permeable nonselective cation channel, which is a member of the transient receptor potential channel subfamily (10) . In 2005, Winn et al. first identified TRPC6 variants segregated with the development of familial FSGS. They also found that TRPC6 was selectively highly expressed in glomerular podocytes (8, 14) and localized to the slit diaphragm complex in close association with nephrin and podocin (14) . Until now, 13 TRPC6 mutations have been identified in 9 pedigrees (British, African American, Mexico, Irish/German, European/ Indian, Western European, Turkish, and Italian) and sporadic cases of FSGS (Spanish, Turkish, and Italian). Patients carrying TRPC6 mutations seem to progress to end-stage renal failure within 10 y (8, (14) (15) (16) (17) (18) . However, the epidemiologic features of TRPC6 variants in Chinese pediatric INS have not yet been explored. Assuming that the identification of TRPC6
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mutations may provide a rationale for therapeutic choice and prognosis prediction, the purpose of this study is to explore the prevalence of TRPC6 variants in Chinese pediatric INS and to investigate the correlation between the TRPC6 genotype and the therapeutic response.
RESULTS

Clinicopathological Correlations
SSNS children were older at disease onset than those with SRNS (5.11 vs. 3.38 y; P = 0.047). The remainders of the demographic and clinical findings are shown in Table 1 . As shown by histopathological analysis, minimal change nephrotic syndrome was significantly more common in the SSNS cases, and FSGS was predominant in the SRNS cases.
Genotype/Phenotype Association of the TRPC6 Variants
We identified three variants in our study: -254C>G (rs3824934) in the promoter region, 43C>T (rs3802829) in exon 1, and 240 G>A (rs17096918) in the exon1-intron1 boundary (Figure 1) . The frequency of the G allele of -254C>G was significantly higher in SRNS than that in SSNS (P = 0.046), whereas the frequencies of the C allele of P15S and the A allele of 240G>A were similar in both SSNS and SRNS (P = 1.00 and P = 0.12, respectively) ( Table 2 ). Genotype analyses were conducted for the dominant model, the recessive model, and the additive model. The -254C>G genotype conferred a greater than threefold increase in the risk of SRNS (dominant model; odds ratio: 3.27; 95% confidence interval: 1.00-10.69; P = 0.046; Table 3 ).
-254C>G Variant in the TRPC6 Promoter Enhanced TRPC6 Transcription -254C>G localizes to the promoter region of TRPC6 and its frequency is significantly higher in SRNS patients. P15S localizes near the promoter region of TRPC6. To explore whether these two variations affect the transcription of TRPC6, we compared the transcription activity of these two variants with the wild-type sequence using a dual-luciferase reporter assay. -254G allele significantly enhanced the activity of TRPC6 promoter compared with the 43T allele (P = 0.008) and wild-type allele (P = 0.001). There was no significant difference between the 43T and wild-type alleles (Figure 2 ).
-254C>G-driven Upregulation of TRPC6 Correlates With the Development of SRNS TRPC6 was ubiquitously expressed in the glomeruli and tubules, including the glomerular epithelium, mesangial cells, tubular interstitial area, and vessels (Figure 3a and Supplementary Figure S1 online). TRPC6 was more highly expressed in SRNS tissues than in SSNS tissues (P = 0.01; Figure 3b ). The SRNS cases with the -254G allele showed higher expression of TRPC6 than the cases with the -254C allele (P = 0.047; Figure 3c ; Table 4 ). A similar, nonsignificant trend was found in the SSNS cases (P = 0.11; Figure 3c ; Table 4 ).
DISCUSSION
The impact of the TRPC6 mutations on the FSGS progress and therapeutical response has been well established and extensively investigated, both in adults and in children. For example, Q889K, M132T, L780P, H218L, and R895L variants of TRPC6 have been identified in different populations, including FSGS and SRNS (15) (16) (17) (18) . However, the prevalence of TRPC6 mutations and the genotype/phenotype correlation in pediatric INS in China have not been illustrated. The aim of this study is to investigate the TRPC6 mutations in sporadic INS in Chinese children and to provide more information concerning the genetic mechanisms underlying the development of the disease and the resistance to therapy mediated by TRPC6 gene defects.
We identified three variants, -254C>G, 43C>T, and 240G>A, in our group of SSNS and SRNS cases (Figure 1) . The allele frequency of the -254G allele was higher in SRNS cases, whereas the allele frequencies of the other two single-nucleotide polymorphisms (SNPs) were comparable between the two groups ( Table 2 ). The high frequency of the -254G allele in SRNS cases indicates its potential significance in the pathogenesis of steroid resistance.
-254C>G localizes within the promoter region of the TRPC6 gene, which contains several transcription binding sites, such as nuclear factor of activated T cells (19, 20) . In cardiomyocytes, TRPC6 was upregulated through the calcineurin-nuclear factor of activated T cells signaling pathway leading to cardiac 
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Articles hypertrophy (20) . TRPC6 mutations in the familial forms of FSGS have been shown to activate basal nuclear factor of activated T cells-mediated transcription significantly compared with wild-type TRPC6 (19) . Yu et al. revealed that a higher frequency of -254G was associated with the development of idiopathic pulmonary arterial hypertension (21) and demonstrated that it modulates TRPC6 gene promoter activity. In addition, Yu et al. showed that the -254G allele enhanced TNF-α-and NF-κB-mediated TRPC6 transcription (21), indicating that this variant had the potential to modulate TRPC6 Articles Kuang et al.
expression in response to immune or inflammatory stress. We found this variant significantly enhanced the activity of the TRPC6 promoter in podocytes (Figure 2) . Furthermore, we determined that there was increased expression of TRPC6 in the glomeruli and renal tubules of children with SRNS and that children with the -254G allele have a higher expression of 
Articles TRPC6 in both the SRNS and SSNS groups (Figure 3) . Taken together, our data showed that the -254C>G SNP may contribute to the upregulation of TRPC6 transcription and protein expression during the development of steroid resistance. TRPC6 is a TRP family calcium channel that mediates calcium influx in response to phospholipase C activation (22, 23) and the secondary messenger diacylglycerol (24) . It has been demonstrated that the elevated expression of TRPC6 could induce podocyte depletion from the glomerulus and lead to proteinuria with the histological features of FSGS in the transgenic animal model (25) . Gain-of-function mutations in TRPC6 led to the constitutive activation of the calcineurin-nuclear factor of activated T cells pathway, which influences actin dynamics in podocytes through the degradation of synaptopodin (19) . Therefore, the upregulation of TRPC6 expression results in a higher calcium influx (8, 14, 17) and actin reorganization in podocytes, finally leading to proteinuria (11, 26) . Therefore, either the increased expression or increased function of TRPC6 is associated with crucial pathways that influence the podocyte phenotype. In addition to the transcription-promoting activity, -254C>G significantly increased basal [Ca 2+ ] cyt and agonist-triggered Ca 2+ entry into pulmonary artery smooth muscle cells (21) . Here, we propose that in podocytes, -254G allele might contribute to the susceptibility of podocytes to injuries and resistance to medications through enhancing the expression and function of TRPC6, which probably leads to the deterioration of INS.
The present study comprised 51 children of INS and indicated a close relationship between the -254 C>G in TRPC6 gene and SRNS. Although the TRPC6 variants were shown in a small group of INS patients in China, we can still speculate that this variant increased the susceptibility of steroid resistance development in pediatric INS in China. To our knowledge, the mechanism of -254C>G in regulation of TRPC6 gene is not so clear, the SNP might not act independently; it might be associated with the other unknown variants to effect together or it is merely a component of the pathway to adjust the individual sensitivity to the hormone. Therefore, large cohorts in whom both gene prevalence and functional studies were conducted are needed to confirm our findings.
Altogether, our findings in this study provided new evidence for the association between TRPC6 SNPs and steroid sensitivity in SRNS children. The genetic variations of TRPC6 may underlie the mechanism of nephrotic syndrome. -254C>G, a SNP underlying enhanced TRPC6 transcription and expression, may correlate with the development of steroid resistance in Chinese children with nephrotic syndrome. As we know, most TRPC6 mutations are found in adult FSGS patients, but in clinical work, children who have repeated renal biopsy show a transition process from minimal change nephrotic syndrome to FSGS (27) . Our study explored a promising possibility of TRPC6 mutation as a biomarker; it can help clinicians to know a potential response to steroids of the patients and consequently adjust the therapeutic response.
METHODS
Patients
Fifty-one patients with INS hospitalized in the Children's Hospital of Fudan University from 2009 to 2010 were enrolled in the study. According to their response to steroid therapy, the patients were divided into two groups: steroid-sensitive (SSNS) and steroid-resistant (SRNS). INS was defined as a condition with heavy proteinuria (urinary protein excretion ≥ 40 mg/m 2 ·h) with hypoalbuminemia ≤25 g/l and without evidence of secondary nephrotic syndrome. Steroidresistant condition was defined as the failure to achieve remission despite 4 wk of prednisolone induction (2 mg/kg·d). Twenty-four out of 28 cases with SRNS and 13 out of 23 cases with SSNS were subjected to renal biopsy. This study was certified by the Ethics Committee of Fudan University, with written, informed consent signed by the parents/legal guardians of all children.
SNP Analysis
Genomic DNA was isolated from peripheral leukocytes using the TIANamp Blood DNA Kit (TIANgene, Beijing, China). The exons of TRPC6 and the exon-intron flanking sequences were amplified by polymerase chain reaction (8) and analyzed by direct sequencing (Invitrogen, Carlsbad, CA).
Immunohistochemistry
The expression of TRPC6 in the glomerulus of the patients was illustrated by immunohistochemistry staining. The renal biopsy specimens were provided by the Pathology Center of Fudan University. Briefly, 3-µm thick sections were deparaffinized, treated with 3% H 2 O 2 (in methanol) to inactivate the endogenous HRP, and subjected to antigen retrieval in a microwave oven in sodium citrate buffer (pH 6.0). Then, the slides were blocked for 30 min at 37 °C in 5% goat serum albumin and incubated with rabbit anti-TRPC6 antibodies (dilution 1:100, Abcam, Cambridge, England) overnight at 4 °C and peroxidase-conjugated goat anti-rabbit IgG for 45 min at 37 °C. The signal was developed by applying 3,3'-diaminobenzidine substrate purchased from Sigma Aldrich, St. Louis, MO, and the sections were counterstained with Meyer's hematoxylin. After mounting, the sections were observed under light microscopy. The Motic Images Advanced 3.2 medical image quantitative analysis system and software (Motic China Group, Xiamen, China) were used to measure the expression of TRPC6. TRPC6 expression of each biopsy specimen were captured, analyzed, and calculated. The mean positive index (%) of five representative fields for each sample was the final index.
Cell Culture
Immortalized mouse podocytes were maintained in RPMI 1640 supplemented with 10% fetal bovine serum in the presence of 50 U/ml of interferon-γ at 33 °C in 5% CO 2 for 5 d and then differentiated at 37 °C in 10% RPMI 1640 in the absence of interferon-γ for 14 d (28).
TRPC6 Promoter Construction
The plasmids of TRPC6 promoter region (−335 to +104; p-254-Luc, p-43-Luc, and p-normal-Luc) were generated based on the protocol from Yu et al. (21) . The control plasmids, pGL3-control (positive control) and pGL3-basic (negative control), were purchased from Promega (Madison, WI). 
